| For: | Nomoto H. Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes. World J Diabetes 2023; 14(3): 188-197 [PMID: 37035222 DOI: 10.4239/wjd.v14.i3.188] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v14/i3/188.htm |
| Number | Citing Articles |
| 1 |
Wanwarang Wongcharoen, Rungroj Krittayaphong, Wacin Buddhari, Songsak Kiatchoosakun, Apiradee Sriwijitkamol, Taweesak Wannachalee, Arintaya Phrommintikul. Expert Opinion on the Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes and Established or High‑risk Atherosclerotic Cardiovascular Disease in Thailand. Journal of Asian Pacific Society of Cardiology 2025; 4 doi: 10.15420/japsc.2024.14
|
| 2 |
|
| 3 |
Mohamed Hassanein, Thamer Alessa, Khadija A. Hafidh, Lamya Alzubaidi, Mahir Jallo, Fatma Al Slail, Hussein Elbadawi, Rayaz A. Malik. Use of Fixed Ratio Combinations to Improve Glycemic Control in Individuals with Type 2 Diabetes: Experts’ Opinion from the Gulf Region. Diabetes Therapy 2025; doi: 10.1007/s13300-025-01824-6
|
| 4 |
Nika Aleksandra Kravos Tramšek, Andrijana Koceva, Mitja Krajnc. Switch from premixed insulin analogue to degludec-liraglutide combination: a CGM study. Frontiers in Endocrinology 2025; 16 doi: 10.3389/fendo.2025.1715800
|
| 5 |
Kyriakos Kintzoglanakis, Christos Diamantis, Anargiros Mariolis, Stavroula A Paschou. Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. Diabetes and Vascular Disease Research 2024; 21(4) doi: 10.1177/14791641241269743
|
| 6 |
Stephen Colagiuri, Antonio Ceriello. 4. Blood glucose-lowering therapies – Insulin options for type 2 diabetes. Diabetes Research and Clinical Practice 2025; 222: 112148 doi: 10.1016/j.diabres.2025.112148
|
